BIO Deutschland takes part in LSX World Congress

The panel discussion “Building a more connected Life Science Ecosystem in Europe” at the “LSX World Congress – Partnering, Strategy & Investment for Life Science Executive Leaders” in London featured encouraging statements and perspectives on how European life science ecosystems can work more closely together in the post-pandemic world: “I see more U.S. venture capitalists coming to Europe because of the overvaluation of U.S. life science companies,” said Bonnie van Wilgenburg (principal, Monograph Capital Partners) in the panel discussion with Michael Altorfer (managing director, Swiss Biotech Association), Viola Bronsema (managing director, BIO Germany), and Anette Steenbergen (managing director, Medicon Valley Alliance).

The drive for greater strategic autonomy in our value and supply chain, the new EU pharmaceutical legislation, and the new initiative for Important Projects of Common European Interest (IPCEI) in the life sciences will bring a great many changes to the EU life science sector in the coming years.
The topic of the panel discussion could not have been more timely, especially considering that collaboration not just within the EU, but also with non-EU countries such as the UK and Switzerland, is valuable and important.

LSX World Congress gathers the founders and CEOs of innovative start-ups through to publicly healthcare giants, and everyone in between. It represents the breadth and depth of the cutting-edge research and technology driving the advances in the industry right now and in the near future.

The industry gathering focuses on one-on-one partnering, bringing the biotech, healthtech, and medtech industry’s c-suite together with the sector’s most active investors, pharma and health technology BD&L teams, R&D leaders, KOLs, and top tier service companies.